Zimbabwe Fully Authorizes Use of Ivermectin Targeting COVID-19 While It Hopes to Vaccinate 60% of Population with Sinovac by End of Year

Zimbabwe Fully Authorizes Use of Ivermectin Targeting COVID-19 While It Hopes to Vaccinate 60% of Population with Sinovac by End of Year

TrialSite chronicled ivermectin’s pathway in the African nation of Zimbabwe, from closely following the South African approach at first, nearly criminalizing access, to a complete turnaround and allowing for the research as a care option, via an off label policy. Now Zimbabwe formally authorizes the use of ivermectin, joining nations as diverse as Slovakia and Indonesia in allowing the use of the drug for the SARS-CoV-2 indication, the pathogen behind COVID-19. Recently, the Medicines Control Authority of Zimbabwe (MCAZ) issued a government notice, declaring, “The secretary for health and child care has authorized the MCAZ to authorize the importation and use of ivermectin for COVID-19. MCAZ will issue bulk section 75 approval for importation of human formulations of ivermectin manufactured by compliant facilities.” TrialSite commends the authorities there for opening up a more diverse and dynamic market for the treatment of SARS-CoV-2 infections while vaccination programs gear up.  TrialSite interviewed a prominent local physician, Dr. Jackie Stone, who has been instrumental in achieving this regulatory milestone, although the physician has on more than one occasion landed in hot...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee